Editor: Atta-ur-Rahman

Frontiers in Clinical Drug Research - Alzheimer Disorders

Volume 8

Personal Book: US $89 Special Offer (PDF + Printed Copy): US $163
Printed Copy: US $119
Library Book: US $356
ISSN: 2451-8743
eISSN: 2214-5168 (Online)
ISBN: 978-981-14-0190-9
eISBN: 978-981-14-0189-3 (Online)
Year of Publication: 2019
DOI: 10.2174/97898114018931190801

Introduction

Frontiers in Clinical Drug Research - Alzheimer Disorders will be of particular interest to readers interested in drug therapy of this specific neurodegenerative condition and related brain disorders as the series provides relevant reviews written by experts in the field of Alzheimer’s disease research.

The eighth volume of this series features chapters covering critical discussions on new therapies for AD. The reviews in this volume include:

  • -Novel Molecular Targets of Tauopathy; Therapeutic and Diagnostic Applications
  • -The Therapy of Alzheimer’s Disease: Towards a New Generation of Drugs
  • -Could Antibiotics Be Therapeutic Agents in Alzheimer’s Disease?
  • -Use of Antipsychotics in Patients with Alzheimer’s Disease
  • -Approaches Based on Cholinergic Hypothesis and Cholinesterase Inhibitors in the Treatment of Alzheimer's Disease
  • -Potential Biological Mechanisms with Prophylactic Action in Rapid Cognitive Impairment in Late-Onset Alzheimer's Disease

Preface

The book series Frontiers in Clinical Drug Research-Alzheimer Disorders presents important recent developments in the form of cutting edge reviews written by the authorities in the field. The chapters in the 8th volume are focused on different therapeutic agents being employed or under development for treating Alzheimer’s disease.

Salama et al., in Chapter 1 discuss the structure, functions and interactions of tau protein with reference to the potential therapeutic targets for the treatment of tauopathies. Piemontese et al., in Chapter 2 present the new generation of drugs as potential therapy for Alzheimer’s disease. Chapter 3 by Burgos-Ramos et al., reviews the neuroprotective role of some antibiotics as therapeutic means in Alzheimer’s disease.

Chapter 4 by Xu et al., describes the use of antipsychotics in patients with Alzheimer’s disease. ÖZDEMİR et al., in chapter 5, discuss the role of cholinergic hypothesis and cholinesterase inhibitors for the treatment of Alzheimer's disease. The last chapter by Stovicek et al., discusses the potential biological mechanisms with prophylactic action in rapid cognitive impairment in late-onset Alzheimer's disease.

I am grateful to all the eminent scientists for their excellent contributions. The efforts of Ms. Fariya Zulfiqar (Manager Publications) & Mr. Shehzad Naqvi (Editorial Manager Publications) and the leadership of Mr. Mahmood Alam (Director Publications) are greatly appreciated.



Prof. Atta-ur-Rahman, FRS
Kings College,
University of Cambridge,
Cambridge,
UK

RELATED BOOKS

.Frontiers in Clinical Drug Research-Dementia.
.Alzheimer
.Advances in Alzheimer Research.
.Cellular and Molecular Biology of Autism Spectrum Disorders.
.Natural Products in Clinical Trials.
.Good Quality Practice (GQP) in Pharmaceutical Manufacturing: A Handbook.
.Natural Products in Clinical Trials.
.Advances in Physicochemical Properties of Biopolymers: Part 1.
.Alzheimer
.Advances in Alzheimer Research.
.Cellular and Molecular Biology of Autism Spectrum Disorders.
.Cellular Mechanisms in Alzheimer’s Disease.